Search Results
Your search for Men matches 2763 pages
Showing 1701 - 1750Nivolumab in Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: Game Not Over
Most patients with squamous cell carcinoma of the head and neck present with locally advanced disease. With combined-modality approaches, the chance of cure ranges from < 50% to up to 80%, depending on the site, stage, and other risk factors, such as human papillomavirus (HPV) status. When...
Validation of the Five-Tiered Gleason Grade Grouping System in Patients With Prostate Cancer
Scientists have been able to validate the recently proposed five-tiered system of Gleason grade grouping using population-based data. The study, led by Grace Lu-Yao, PhD, MPH, Associate Director for Population Science at the Sidney Kimmel Cancer Center at Thomas Jefferson University and Vice...
Prostate Cancer Treatment Rates Drop, Reflecting Change in Screening Recommendations
As some national guidelines now recommend against routine prostate cancer screening, the overall rate of men receiving treatment for the disease declined 42% between 2007 and 2012, a new study published by Borza et al in Health Affairs found. The decline reflects efforts to decrease overdiagnosis...
Has the Affordable Care Act Reduced Socioeconomic Disparities in Cancer Screening?
Out-of-pocket expenditures are thought to be a significant barrier to receiving cancer preventive services, especially for individuals of lower socioeconomic status. A new study published by Cooper et al in Cancer looked at how the Affordable Care Act (ACA), which eliminated such out-of-pocket...
Results of International Cross-Sectional Survey Reveal Gaps in Primary and Secondary Skin Cancer Prevention, Perceptions, and Knowledge
A large international survey on sun exposure behaviors and skin cancer detection found there are many imperfections and geographic disparities in primary and secondary prevention of skin cancer. This information could help inform future awareness campaigns developed to address the global need to...
Cancer Death Rate Has Dropped 25% Since 1991 Peak, According to American Cancer Society Report
A steady decline over more than 2 decades has resulted in a 25% drop in the overall cancer death rate in the United States. The drop equates to 2.1 million fewer cancer deaths between 1991 and 2014. The news comes from "Cancer Statistics, 2017," the American Cancer Society’s...
Customer Response to Personal Genomic Testing for Cancer Risk
In a study reported in the Journal of Clinical Oncology, Gray et al found that most people receiving cancer-related data through direct-to-consumer personal genomic testing tended not to change health or screening behaviors when an elevated risk was identified. The study involved baseline and...
Vascular-Targeted Photodynamic Therapy Shows Promise in Low-Risk Prostate Cancer
In a European phase III trial reported in The Lancet Oncology, Azzouzi et al found that padeliporfin vascular-targeted photodynamic therapy was associated with a reduced rate of disease progression vs active surveillance in men with low-risk prostate cancer. Study Details In the open-label trial, ...
Women in Oncology: Breaking Down Barriers and Looking to the Future
There has been no better time than the present for women in the field of oncology: Women at all stages of their careers are finding more opportunities and avenues to excel. At the time of the last ASCO workforce survey, women made up 28.4% of the oncologist workforce, and that proportion is rising...
A Gleason 6 Tumor: Is It Cancer, and Should It Be Treated?
The diagnosis and treatment of prostate cancer have long been a source of controversy among the oncology community, the political sector, and patient advocacy groups. Most notably, the decision to biopsy a man’s prostate gland rests largely on his prostate-specific antigen (PSA) test numbers, the...
Investigational Immunotherapy for Advanced Melanoma
The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Danny N. Khalil, MD, PhD, and colleagues in Clinical Cancer Research....
Successful Retreatment With Cisplatin-Based Therapy Reported in Men Relapsing After Adjuvant Carboplatin for Stage I Seminoma
In an analysis reported in the Journal of Clinical Oncology, Fischer et al found that men with clinical stage I seminoma who relapsed after adjuvant carboplatin could be successfully re-treated with cisplatin-based chemotherapy. Study Details The analysis included data from 185 patients who...
Does Androgen-Deprivation Therapy Increase the Risk for Dementia in Patients With Prostate Cancer?
In a UK population–based study reported in the Journal of Clinical Oncology, Khosrow-Khavar et al found no significant association between the use of androgen-deprivation therapy and the risk for dementia in patients with prostate cancer. The study involved a cohort of 30,903 men with newly...
Can Mindfulness-Based Cognitive Therapy Reduce Distress in Patients With Advanced Prostate Cancer?
Chambers et al found that a mindfulness-based cognitive therapy intervention did not improve measures of distress or anxiety vs minimally enhanced usual care among men with advanced prostate cancer, according to an Australian study reported in the Journal of Clinical Oncology. In the study, 189...
Long-Term Effects of Finasteride in Patients From the Prostate Cancer Prevention Trial
In the Prostate Cancer Prevention Trial finasteride was found to reduce the risk of low-grade prostate cancer but to have no effect on overall survival. Results of the trial, in which 18,880 men were randomized to receive finasteride or placebo for 7 years, were reported in 2003. In a recent study...
Dave, Dave, Dave
It was 1983, and I was in my third year as an attending physician at a major East Coast university medical center and just 5 years out of fellowship. As was common at the time, I saw and treated all malignancies except leukemia and gynecologic cancers. In the middle of a typically busy day at the ...
At ESMO 2016, Many Phase III Trials Fail to Meet Primary Endpoints
The 2016 European Society for Medical Oncology (ESMO) Congress revealed many important positive findings from key trials in a number of tumor types, but many highly anticipated phase III trials in advanced disease failed to meet their primary endpoints. The ASCO Post has summarized several of these ...
Study Finds EXITS Gene Mutations May Contribute to Cancer Sex Bias
According to Surveillance, Epidemiology, and end Results (SEER) data from 2008 to 2012, American males have an excess risk of 20.4% of developing any cancer compared with females, and there is a ≥ 2:1 male predominance for some individual cancers. This excess risk results in approximately...
Weight Loss May Help Prevent Multiple Myeloma
New research shows that excess weight increases the risk that a benign blood disorder will progress to multiple myeloma. The study, by a team at Washington University School of Medicine in St. Louis, is published in the Journal of the National Cancer Institute. Being overweight or obese has been...
Adding Olaratumab to Doxorubicin Increases Overall Survival in Advanced Soft-Tissue Sarcoma
As reported by William D. Tap, MD, of Memorial Sloan Kettering Cancer Center, and colleagues in The Lancet, the addition of the anti-PDGFRα (platelet-derived growth factor receptor alpha) antibody olaratumab to doxorubicin resulted in prolonged progression-free and overall survival in phase II...
When Marijuana Was Legal in the United States
Marijuana, or cannabis, used to be legal in the United States and was “actually listed in the U.S. formulary in 1854,” according to Judith A. Paice, PhD, RN, Director, Cancer Pain Program, Division of Hematology-Oncology at Northwestern University, Feinberg School of Medicine, Chicago. “Many of...
The Smartest Guys in the Room
The smartest guys in the room were never from the big energy companies, and they’re not running hedge funds on Wall Street or building the next Facebook. For me, the smartest guys in the room are the selfless men and women who’ve transformed cancer from what was all too often a death sentence to...
Lower Risk of All-Cause Mortality in Multiple Myeloma Reported With Treatment at Higher-Volume Facilities
In an analysis of data from the National Cancer Database reported in the Journal of Clinical Oncology, Go et al found a lower risk of all-cause mortality among patients with multiple myeloma treated at higher-volume facilities. Study Details The study included patients diagnosed with multiple...
Second Opinions From Urologists for Prostate Cancer: Do They Make a Difference?
A new analysis indicates that many men with prostate cancer obtain second opinions from urologists before starting treatment, but surprisingly, second opinions are not associated with changes in treatment choice or improvements in perceived quality of prostate cancer care. Published by...
7 Substances Added to HHS 14th Report on Carcinogens
The release of the U.S. Department of Health and Human Services (HHS) 14th Report on Carcinogens on November 3, 2016, included 7 newly reviewed substances, bringing the cumulative total to 248 listings. The chemical trichloroethylene (TCE), the metallic element cobalt, and cobalt compounds...
Phase III Study of Sunitinib Is First to Show Benefit in Adjuvant Setting for Treatment of Renal Cell Carcinoma
Sunitinib (Sutent) improved disease-free survival by more than 1 year when used as adjuvant treatment for high-risk locoregional renal cell carcinoma following nephrectomy, but with the cost of toxicity. S-TRAC is the first phase III trial showing a benefit for adjuvant therapy in renal cell...
Ribociclib Granted FDA Priority Review for First-Line Treatment of Hormone Receptor–Positive/HER2-Negative Advanced Breast Cancer
On November 1, the U.S. Food and Drug Administration (FDA) accepted a New Drug Application (NDA) for filing and granted Priority Review for ribociclib (LEE011) as first-line treatment of postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2...
Adulthood BMI Increases Leading to Obesity Seem to Be Linked to an Increased Risk of Fatal Prostate Cancer
In a study of data from men in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial reported in the Journal of the National Cancer Institute, Kelly et al found that body mass index (BMI) increases during adulthood that lead to obesity are associated with an increased risk of...
Study Shows International Trends in Anal Cancer Incidence Rates
A new American Cancer Society study finds that incidence of anal cancer has been increasing in women or in both men and women in 13 of 18 countries studied, particularly in the Americas, Northern/Western Europe, and Australia. The authors say population-based preventive measures, including human...
Potential Link Between Androgen-Deprivation Therapy for Prostate Cancer and Risk for Dementia
In a single-center analysis reported in JAMA Oncology, Nead et al found that the use of androgen-deprivation therapy for prostate cancer was associated with an increased risk for dementia. The study involved electronic medical record data from the Stanford University Health System from 1994 to...
Link Between Molecular Mechanisms in Prostate Cancer and Ewing Sarcoma Found
Medical researchers at Indiana University (IU) Bloomington have found evidence for a link between prostate cancer, which affects millions of men aged 50 and older, and Ewing's sarcoma, a rare form of cancer that affects children and young adults. The results of the study, reported by Kedage et al...
Proportion of Cancer Deaths From Smoking Varies Across States and Is Highest in the South
Although smoking prevalence in the U.S. has declined by more than half since 1965, nearly 40 million adults still smoke cigarettes, resulting in about 167,133 cancer deaths in 2014, according to a study by the American Cancer Society. The study investigated cancer deaths among adults 35 and older...
Similar Functional Outcomes With Robot-Assisted Laparoscopic and Open Radical Retropubic Prostatectomy
Robot-assisted laparoscopic prostatectomy and open radical retropubic prostatectomy yielded similar domain-specific quality-of-life or pathologic outcomes at 12 weeks in men with newly diagnosed, clinically localized prostate cancer, according to the results of a randomized phase III trial reported ...
Prognostic and Predictive Molecular Subtypes of Prostate Cancer Identified
Members of the oncology community have long complained that prostate cancer lags behind breast cancer regarding biomarkers for prognosis and treatment, but the good news is that this gap is narrowing. In the largest study of its kind to date, presented at the 58th Annual Meeting of the American...
Safety of Extreme Hypofractionation Reassuring in Intermediate-Risk Prostate Cancer
Giving patients larger fractions of radiation over shorter periods (ie, hypofractionation) is gaining ground in several types of cancers. This approach is attractive for patients’ convenience, shortening treatment and travel times, and also for resource utilization. Several studies have shown that ...
Investigational Immunotherapy Appears Safe and Somewhat Active in Advanced Melanoma
The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Khalil et al in Clinical Cancer Research. IMD-20D7S is a...
Study Finds PFS Benefit, but No Overall Survival Benefit, for Ipilimumab in Metastatic Castration-Resistant Prostate Cancer
Ipilimumab (Yervoy) was associated with prolonged progression-free survival—but not overall survival—compared with placebo in men with asymptomatic or minimally symptomatic chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases, according to a...
Long-Term Effects of Finasteride in Patients From the Prostate Cancer Prevention Trial
In a study reported in the Journal of the National Cancer Institute, Unger et al found that use of finasteride vs placebo in the Prostate Cancer Prevention Trial was associated with a modestly increased risk of depression and a modestly reduced risk of procedures for benign prostatic...
Christopher J. Sweeney, MBBS, on Prostate Cancer: CHAARTED Trial Follow-up
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how long-term study results showed no survival benefit in men with ogliometastatic prostate cancer. (Abstract 720PD)
The Medical Profession Has to Become Culturally Sensitive to the Needs of LGBT Cancer Survivors
Despite my breast cancer diagnosis 4 years ago, I feel really lucky. My cancer was detected relatively early, stage IIB, during a routine mammogram screening—a test that many of my lesbian friends skip because they don’t want to deal with a medical system steeped in a heterosexual culture that is...
Study Finds TP53 and MDM2 Alterations Linked to Cisplatin Resistance in Advanced Germ Cell Tumors
In a study reported in the Journal of Clinical Oncology, Bagrodia et al found that alterations in TP53 and MDM2 were associated with cisplatin resistance and poorer outcome in patients with advanced germ cell tumors. Actionable alterations were found in a high proportion of cases of cisplatin...
Surgery and Radiation ProtecT Against Progression/Metastasis vs Active Monitoring in Prostate Cancer, but at What Cost?
The ProtecT trial showing similar 10-year survival with active monitoring, surgery, or radiotherapy for prostate-specific antigen (PSA)-detected localized prostate cancer but a greater risk of disease progression/metastasis with monitoring was recently reported by Hamdy and colleagues and is...
Risk of Metastasis With Active Monitoring in PSA-Detected Localized Prostate Cancer: The ProtectT Trial
The ProtecT study findings1 are provocative. Despite having a control arm of active monitoring with serial prostate-specific antigen (PSA) testing, as compared with watchful waiting in the prior randomized trials (ie, SPCG-42 and PIVOT3), and also enrolling men with more favorable-risk disease...
Similar 10-Year Survival With Active Monitoring, Surgery, or Radiotherapy for PSA-Detected Clinically Localized Prostate Cancer
In the UK ProtecT trial reported in The New England Journal of Medicine, Freddie C. Hamdy, FRCS, FMedSci, of the University of Oxford, and colleagues found no significant differences in prostate cancer–specific or overall mortality among men with clinically localized prostate cancer detected by...
Study Reports No Association Between Vasectomy and Prostate Cancer Incidence or Mortality
In an analysis of the Cancer Prevention Study II (CPS-II) study cohort reported in the Journal of Clinical Oncology, Jacobs et al found no significant association between vasectomy and overall prostate cancer incidence or mortality. A recent prospective study had shown an association of vasectomy...
ASTRO 2016: Extremely Hypofractionated Radiation Therapy Shows Promising Toxicity Results for Intermediate-Risk Prostate Cancer
For men with intermediate-risk prostate cancer, side effects at 2 years following radiation therapy were comparable for extremely hypofractionated treatment, which was delivered in 7 fractions across 2.5 weeks, and conventional treatment of 39 fractions across 8 weeks, according to research...
ASTRO 2016: SBRT Offers Patients With Prostate Cancer High Disease Control and Low Toxicity in Fewer Treatments
High-dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates, according to research presented by Meier et al at the 58th Annual Meeting of the...
ASTRO 2016: Three Novel Intrinsic Subtypes of Prostate Cancer Identified
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research...
ASTRO 2016: Intermediate-Risk Prostate Cancer May Be Well Controlled With Brachytherapy Alone
For men with intermediate-risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research...
Patient-Reported Outcomes After Active Monitoring, Surgery, or Radiotherapy in PSA-Detected Localized Prostate Cancer
Patient-reported outcomes differed among men with localized prostate cancer detected by prostate-specific antigen (PSA) testing who were randomized to receive active monitoring, surgery, or radiotherapy in the UK ProtecT trial, according to a report by Donovan et al in The New England Journal of...
